Primary Ciliary Dyskinesia PCD Market Report for M&A, Expansion, and Competitive Benchmarking (2025–2034)

June 19, 2025 01:28 AM PDT | By EIN Presswire

Google News:

Primary Ciliary Dyskinesia PCD Market Report for M&A, Expansion, and Competitive Benchmarking (2025–2034) — Image source: EIN Presswire

Recent News

Perpetua Resources (NASDAQ:PPTA) in the Metal & Mining Sector

Lennar (NYSE:LEN) Stock Movement After Downgrade Impacts NYSE Composit...

Oscar Health (NYSE:OSCR) Stock Surges Amid Strong Growth NYSE Composit...

Dynatrace (NYSE:DT) Sees Higher Return On Capital Trends Grow Nasdaq C...

LONDON, GREATER LONDON, UNITED KINGDOM, June 19, 2025 /EINPresswire.com/ -- What Is The Growth Trajectory Of The Primary Ciliary Dyskinesia Market?
The primary ciliary dyskinesia PCD market size has experienced strong growth in recent years. It is projected to grow from $0.46 billion in 2024 to $0.50 billion in 2025, reflecting a compound annual growth rate CAGR of 7.1%. The historic growth can be attributed to escalating clinical confusion with other respiratory disorders, expanded reliance on symptomatic treatment, and increasing focus on cystic fibrosis overshadowing primary ciliary dyskinesia.

What is Projected Primary Ciliary Dyskinesia Market Size and Growth?
The PCD market size is anticipated to see significant growth in the next few years, expanding to $0.65 billion in 2029 at a CAGR of 6.8%. This forecasted growth can be ascribed to growing awareness of rare respiratory diseases, improved genetic testing availability, rising incidences of chronic respiratory infections, and better reimbursement policies. These factors are complemented by the expansion of specialized diagnostic centers and technological advancements like the development of non-invasive diagnostic tools and integration of artificial intelligence in diagnostic imaging.

Get Your Free Sample Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24386&type=smp

What's Driving the Primary Ciliary Dyskinesia Market?
This market growth is set to be propelled by the rising demand for gene therapy, a treatment that modifies or replaces faulty genes in a patient's cells to cure or prevent diseases. This burgeoning demand is fuelled by progress in genetic research that enables more accurate treatments targeting and correcting genetic disorders at a molecular level, thereby enhancing patient outcomes. Researchers are developing gene therapy for PCD to correct the genetic mutations that cause faulty cilia function, leading to improved mucus clearance and reduced respiratory infections. For instance, according to the American Society of Gene & Cell Therapy ASGCT, in the first quarter of 2023, there were 247 gene therapy programs in Phase II clinical trials, a figure which increased by 5% by the end of the second quarter. This growing demand for gene therapy is driving the growth of the PCD market.

Order Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/primary-ciliary-dyskinesia-pcd-global-market-report

Which Major Companies Are Operating in the Primary Ciliary Dyskinesia Market?
Key industry players operating in this market include Centogene N.V., Nationwide Children’s Hospital, Revvity Inc., Quest Diagnostics Incorporated, Children’s Healthcare of Atlanta, Exact Sciences Corp., University Hospital Southampton, UT Health East Texas, Guy's and St Thomas' NHS Foundation Trust, National Jewish Health, Vanderbilt University Medical Center, UNC School of Medicine, Stanford Medicine, Mayo Foundation for Medical Education and Research, DNA Labs India Pvt. Ltd., Parion Sciences Inc., ReCode Therapeutics Inc., University Hospital Münster, UAB Health System, and PCD Foundation.

What Are the Emerging Trends in the Primary Ciliary Dyskinesia Market?
Major companies in the PCD market are focusing on developing innovative solutions like investigational mRNA-based therapeutics to enhance symptom management and elevate patients’ quality of life. One such instance was in June 2024 when ReCode Therapeutics, Inc., a US-based biotechnology company, launched RCT1100, an investigational inhaled mRNA therapy that received FDA approval for orphan drug designation to treat PCD. RCT1100 aims to restore ciliary function by delivering DNAI1 mRNA directly to airway cells, addressing a critical unmet need for the estimated 45,000 affected individuals in the U.S.

How Is the Primary Ciliary Dyskinesia Market Segmented?
The PCD market report covers market segmentation by Treatment Antibiotics, Airway Clearance Therapies, Surgical Interventions, Other Treatments, by Method Genetic Testing, Imaging Techniques, Clinical Evaluation, Lung Function Tests, by Distribution Channel Direct Sales, Online Pharmacies, Third-party Distributors, Retail Pharmacies, and by End-User Hospitals, Specialty Clinics, Diagnostic Laboratories, Other End-Users.

What Regional Insights Does the Primary Ciliary Dyskinesia Market Offer?
Regionally, North America was the largest market for PCD in 2024, however, Asia-Pacific is expected to be the fastest-growing region in the forecasted period, illustrating the global reach of the PCD market with coverage across Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

Browse Through More Similar Reports By The Business Research Company:
Primary School Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/primary-school-global-market-report

Lithium Primary Batteries Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/lithium-primary-batteries-global-market-report

Alkaline Primary Batteries Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/alkaline-batteries-global-market-report

About The Business Research Company
The Business Research Company boasts a repository of over 15000+ reports across 27 industries and 60+ geographies. Its extensive secondary research and unique insights from industry leaders arm you with the data necessary to stay ahead in the game.

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
[email protected]
Visit us on social media:
LinkedIn
Facebook
X

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations, and video (Content) is a service of Kalkine Media LLC., having Delaware File No. 4697309 (“Kalkine Media, we or us”) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.